Ocean-derived nutraceutical specialist Aker BioMarine has teamed up with contract research organisation KGK Science to conduct the first-ever clinical trial on Lysoveta.
The lyso-phosphatidylcholine (LPC)-encapsulated omega-3 ingredient is designed to surpass the blood brain barrier, meaning EPA and DHA — two essential fatty acids for cognitive and ocular health — can reach the brain and eyes.
In this clinical trial, the pair will assess the impact of daily supplementation with Lysoveta in 138 healthy participants aged between 50 and 75; all of which have mild memory complaints.
Primarily, the study will look at how Lysoveta can influence cognitive function, with researchers honing in on memory improvements as a key focus.
They will also look at how supplementation with the nutraceutical can influence mood, levels of key cognition biomarkers and omega-3 status.
Running for 18 months, this mid-term study will likely yield interim, mood-focused results in the first quarter of 2026.
“Launching our first clinical study for Lysoveta is a major milestone in our journey to develop new health solutions,” said Simon Seward, CEO of Human Health Ingredients at Aker BioMarine.
“We believe that Lysoveta will play an important role in supporting brain and eye health, and this study will bring us one step closer to delivering a healthy ageing solution to individuals across the globe."
To keep up with demand for Lysoveta during the trial period, Aker BioMarine has also scaled its manufacturing operations.
A new frontier in brain and eye health
Lysoveta represents a new generation of omega-3 innovation. By binding DHA and EPA to lysophosphatidylcholine (LPC), the product is uniquely formulated to cross the blood-brain and blood-retina barriers — critical to delivering key nutrients where they are needed most.
Aker BioMarine holds 40 patents with broad protection relating to the composition, usage, and production of LPC-bound omega-3 products in 16 countries worldwide — demonstrating the company’s leadership and long-term commitment to innovation in this field.
The launch of this study builds on previous collaboration efforts with leading researchers, including Dr. Michael Davidson and Trofi Nutritionals, aiming to expand Lysoveta’s potential use in conditions like Alzheimer’s disease, male infertility, and gestational diabetes.
Lysoveta already holds New Dietary Ingredient (NDI) status in the United States, with regulatory processes ongoing in Europe, China and Australia.
"This clinical trial will help us to translate our scientific research into real-world health solutions that show strong efficacy in supporting brain and eye health," concluded Line Johnsen, SVP Human Health Ingredients R&D.
